Cargando…

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients

INTRODUCTION: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing tho...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Melissa A., Brown, Amanda L., Johnston, Jennifer, Clancy, Richard, McGregor, Iain, Bruno, Raimondo, Lintzeris, Nick, Montebello, Mark, Luksza, Jennifer, Bowman, Jenny, Phung, Nghi, Allsop, Dave, Dunlop, Adrian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314558/
https://www.ncbi.nlm.nih.gov/pubmed/34311790
http://dx.doi.org/10.1186/s42238-021-00091-z
_version_ 1783729576244936704
author Jackson, Melissa A.
Brown, Amanda L.
Johnston, Jennifer
Clancy, Richard
McGregor, Iain
Bruno, Raimondo
Lintzeris, Nick
Montebello, Mark
Luksza, Jennifer
Bowman, Jenny
Phung, Nghi
Allsop, Dave
Dunlop, Adrian J.
author_facet Jackson, Melissa A.
Brown, Amanda L.
Johnston, Jennifer
Clancy, Richard
McGregor, Iain
Bruno, Raimondo
Lintzeris, Nick
Montebello, Mark
Luksza, Jennifer
Bowman, Jenny
Phung, Nghi
Allsop, Dave
Dunlop, Adrian J.
author_sort Jackson, Melissa A.
collection PubMed
description INTRODUCTION: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing those who report ever using SCRAs with those who have never used SCRAs. METHODS: A questionnaire orally administered in person to a convenience sample of 154 cannabis treatment service clients from New South Wales, Australia (71% male, median age 35) collected information regarding cannabis and SCRA use including motivations, effects and health-related consequences of use, demographics, other substance use and overall health. Demographic profiles and between-group differences were explored. McNemar tests compared effects of SCRA and cannabis. Logistic regression analysis determined predictors of SCRA use. RESULTS: Half (53%) reported lifetime SCRA use; 20% reported previous-month use. The SCRA + cannabis group displayed greater polysubstance use and psychological distress. Reduced dependence on cannabis but higher levels of other substance use may predict SCRA use. Although curiosity motivated initial SCRA consumption, perceived psychoactive strength drove continued use. SCRAs appear to induce more negative side-effects than cannabis. Of the SCRA + cannabis group, 27% sought medical assistance for SCRA use. Most (90%) preferred cannabis to SCRAs, citing superior safety, effects and consistency of cannabis. CONCLUSIONS: Among clients seeking treatment for cannabis use, SCRA use was relatively common, although not a preferred substance. Hazardous substance use and poor mental health characterised SCRA consumers, highlighting the need for continued monitoring by researchers and treatment providers of SCRA consumption in populations who use substances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42238-021-00091-z.
format Online
Article
Text
id pubmed-8314558
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83145582021-07-28 The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients Jackson, Melissa A. Brown, Amanda L. Johnston, Jennifer Clancy, Richard McGregor, Iain Bruno, Raimondo Lintzeris, Nick Montebello, Mark Luksza, Jennifer Bowman, Jenny Phung, Nghi Allsop, Dave Dunlop, Adrian J. J Cannabis Res Original Research INTRODUCTION: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing those who report ever using SCRAs with those who have never used SCRAs. METHODS: A questionnaire orally administered in person to a convenience sample of 154 cannabis treatment service clients from New South Wales, Australia (71% male, median age 35) collected information regarding cannabis and SCRA use including motivations, effects and health-related consequences of use, demographics, other substance use and overall health. Demographic profiles and between-group differences were explored. McNemar tests compared effects of SCRA and cannabis. Logistic regression analysis determined predictors of SCRA use. RESULTS: Half (53%) reported lifetime SCRA use; 20% reported previous-month use. The SCRA + cannabis group displayed greater polysubstance use and psychological distress. Reduced dependence on cannabis but higher levels of other substance use may predict SCRA use. Although curiosity motivated initial SCRA consumption, perceived psychoactive strength drove continued use. SCRAs appear to induce more negative side-effects than cannabis. Of the SCRA + cannabis group, 27% sought medical assistance for SCRA use. Most (90%) preferred cannabis to SCRAs, citing superior safety, effects and consistency of cannabis. CONCLUSIONS: Among clients seeking treatment for cannabis use, SCRA use was relatively common, although not a preferred substance. Hazardous substance use and poor mental health characterised SCRA consumers, highlighting the need for continued monitoring by researchers and treatment providers of SCRA consumption in populations who use substances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42238-021-00091-z. BioMed Central 2021-07-26 /pmc/articles/PMC8314558/ /pubmed/34311790 http://dx.doi.org/10.1186/s42238-021-00091-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Jackson, Melissa A.
Brown, Amanda L.
Johnston, Jennifer
Clancy, Richard
McGregor, Iain
Bruno, Raimondo
Lintzeris, Nick
Montebello, Mark
Luksza, Jennifer
Bowman, Jenny
Phung, Nghi
Allsop, Dave
Dunlop, Adrian J.
The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
title The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
title_full The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
title_fullStr The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
title_full_unstemmed The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
title_short The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
title_sort use and effects of synthetic cannabinoid receptor agonists by new south wales cannabis treatment clients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314558/
https://www.ncbi.nlm.nih.gov/pubmed/34311790
http://dx.doi.org/10.1186/s42238-021-00091-z
work_keys_str_mv AT jacksonmelissaa theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT brownamandal theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT johnstonjennifer theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT clancyrichard theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT mcgregoriain theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT brunoraimondo theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT lintzerisnick theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT montebellomark theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT lukszajennifer theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT bowmanjenny theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT phungnghi theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT allsopdave theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT dunlopadrianj theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT jacksonmelissaa useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT brownamandal useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT johnstonjennifer useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT clancyrichard useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT mcgregoriain useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT brunoraimondo useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT lintzerisnick useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT montebellomark useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT lukszajennifer useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT bowmanjenny useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT phungnghi useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT allsopdave useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients
AT dunlopadrianj useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients